{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"4"}],"units":"Participants"}],"description":"For patients with recurrent solid tumors a patient who experienced a complete or partial response according to RECIST version 1.1 criteria is considered a responder. For patients with recurrent acute lymphoblastic leukemia a patient who experiences a bone marrow evaluation with \\< 5% blast cells on morphological evaluation of bone marrow will be considered a responder. For patients with recurrent acute myelogenous leukemia a patient who experiences a complete remission or complete remission with partial recovery of platelet count according to the AML International Working Group Criteria will be considered a responder.","groups":[{"description":"Experimental: Arm 1","id":"OG000","title":"Recurrent Neuroblastoma With Measurable Disease at Enrollment"},{"description":"Experimental: Arm 2","id":"OG001","title":"Recurrent Neuroblastoma Only MIBG Evaluable Disease at Enroll"},{"description":"Experimental: Arm 3","id":"OG002","title":"Previously Treated Childhood Rhabdomyosarcoma"},{"description":"Experimental: Arm 4","id":"OG003","title":"Recurrent Osteosarcoma"},{"description":"Experimental: Arm 5","id":"OG004","title":"Recurrent Ewing Sarcoma /Peripheral Neuroectodermal Tumor"},{"description":"Experimental: Arm 6","id":"OG005","title":"Recurrent Childhood Soft Tissue Sarcoma"},{"description":"Experimental: Arm 7","id":"OG006","title":"Childhood Hepatoblastoma"},{"description":"Experimental: Arm 8","id":"OG007","title":"Recurrent Childhood Germ Cell Tumor"},{"description":"Experimental: Arm 9","id":"OG008","title":"Recurrent Wilms Tumor and Other Childhood Kidney Tumors"},{"description":"Experimental: Arm 10","id":"OG009","title":"Recurrent Childhood Acute Lympohblastic Leukemia"},{"description":"Experimental: Arm 11","id":"OG010","title":"Recurrent Childhood Acute Myeloid Leukemia"},{"description":"Experimental: Arm 12","id":"OG011","title":"Rhaboid Malignancy"}],"paramType":"NUMBER","populationDescription":"Of the 118 enrolled patients, two were not evaluable for the primary outcome measure. Neither received protocol therapy. One was enrolled in arm 11, one was enrolled in Arm 1.","reportingStatus":"POSTED","timeFrame":"From first dose of alisertib through 6 cycles of protocol therapy or until removal from protocol therapy whichever occurred first.","title":"Number of Participants With Overall Response","type":"PRIMARY","unitOfMeasure":"Patients"}